Tirzepatide
A dual GIP and GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes and chronic weight management.
Also referenced as: Mounjaro, Zepbound
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when CP-2T crosses your target, drops, or sets a new tracked low—without daily noise.
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Mounjaro, Zepbound
FDA label signal · 299 trials · 2484 PubMed results
Tirzepatide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Tirzepatide has 59 name-matched clinical trials (2 international) (highest phase: Phase 4) and 2496 PubMed-indexed publications and holds an FDA drug label. 17 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What tirzepatide is
Tirzepatide is a dual agonist that targets both GIP and GLP-1 pathways. It is marketed in FDA-approved products including Mounjaro and Zepbound, with the indication depending on the specific label.
Why it stands out
Tirzepatide matters because it moved beyond the single-pathway GLP-1 story and helped establish the market for dual- and triple-agonist obesity therapeutics.
Regulatory context
FDA announced the approval of Zepbound for chronic weight management on November 8, 2023:
FDA has also published safety and enforcement material addressing unapproved versions of tirzepatide sold outside approved channels:
Why that matters for researchers
Tirzepatide is a good example of how fast the public conversation can outrun the regulatory one. The ingredient may be familiar, but product category still matters:
- FDA-approved branded product
- compounded product
- research-market listing
Those carry different expectations for quality control, labeling, and oversight.
Where tirzepatide fits in the landscape
If semaglutide helped normalize GLP-1-based weight management, tirzepatide helped raise the performance ceiling and opened the door for the newer triple-agonist pipeline that includes compounds like retatrutide.